Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-014220
Filing Date
2021-11-03
Accepted
2021-11-03 09:55:45
Documents
59
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20210930x10q.htm   iXBRL 10-Q 1002908
2 EX-31.1 anvs-20210930xex31d1.htm EX-31.1 13514
3 EX-31.2 anvs-20210930xex31d2.htm EX-31.2 13548
4 EX-32.1 anvs-20210930xex32d1.htm EX-32.1 5713
5 EX-32.2 anvs-20210930xex32d2.htm EX-32.2 5699
  Complete submission text file 0001558370-21-014220.txt   4002461

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20210930.xsd EX-101.SCH 36455
7 EX-101.CAL anvs-20210930_cal.xml EX-101.CAL 25081
8 EX-101.DEF anvs-20210930_def.xml EX-101.DEF 127649
9 EX-101.LAB anvs-20210930_lab.xml EX-101.LAB 309516
10 EX-101.PRE anvs-20210930_pre.xml EX-101.PRE 226600
11 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20210930x10q_htm.xml XML 475261
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 211374014
SIC: 2834 Pharmaceutical Preparations